Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
Not availableAdditional role information may appear below
Board positions
Not establishedNo board position is currently listed on this profile
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Dr. Car joined Biohaven in August 2022 after serving as Chief Scientific Officer at Agios Pharmaceuticals and spending 25 years at Bristol-Myers Squibb, where he built a translational medicine team covering biomarkers through data science and pharmaco-diagnostics. He holds a degree in Veterinary Medicine from the University of Melbourne and a Ph.D. from Cornell University.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

A current role is not yet confirmed. Additional information may be available in the Sources section.

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Connections

Explore the roles, education and affiliations published in this record.

No public connections are published in this record yet.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

People connections are private by default.

No person-to-person relationship is exposed by this public record. Shared boards, employment, and Council activity require a permissioned view.

Claim to review relationship visibility

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingNTLA DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 2 · Sec FilingMASS DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 3 · Sec FilingXNCR DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 4 · Sec FilingEXEL DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 5 · Sec FilingVKTX DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 6 · Sec FilingBHVN DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 7 · Sec FilingEXPO 10-K executive officersSupports Executive company, Executive title.Open sourceSource 8 · Sec FilingHenry Schein, Inc. director board sourceSupports Board membership, Board independence.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:bradley-t-sheares-phd
Record version
public-0

Published evidence records

8 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. NTLA DEF 14A executive officers

    sec filing · Source published: Apr 30, 2026 · Retrieved: May 5, 2026

    Supports 2 claims
    • Executive company: Executive at Intellia Therapeutics, Inc. · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Named Executive Officer · Claim reviewed: May 5, 2026

  2. MASS DEF 14A executive officers

    sec filing · Source published: Apr 29, 2026 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at 908 Devices Inc. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Director · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  3. XNCR DEF 14A executive officers

    sec filing · Source published: Apr 27, 2026 · Retrieved: May 5, 2026

    Supports 2 claims
    • Executive company: Executive at Xencor Inc · Claim reviewed: May 5, 2026
    • Executive title: Executive title: President, Chief Executive Officer and Director · Claim reviewed: May 5, 2026

  4. EXEL DEF 14A executive officers

    sec filing · Source published: Apr 15, 2026 · Retrieved: May 4, 2026

    Supports 2 claims
    • Executive company: Executive at Exelixis Inc · Claim reviewed: May 4, 2026
    • Executive title: Executive title: Senior Vice President and General Counsel · Claim reviewed: May 4, 2026

  5. VKTX DEF 14A executive officers

    sec filing · Source published: Apr 1, 2026 · Retrieved: May 5, 2026

    Supports 2 claims
    • Executive company: Executive at Viking Therapeutics, Inc. · Claim reviewed: May 5, 2026
    • Executive title: Executive title: President and Chief Executive Officer, Director · Claim reviewed: May 5, 2026

  6. BHVN DEF 14A executive officers

    sec filing · Source published: Mar 13, 2026 · Retrieved: May 15, 2026

    Supports 2 claims
    • Executive company: Executive at Biohaven Ltd. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Scientific Officer · Claim reviewed: May 15, 2026

  7. EXPO 10-K executive officers

    sec filing · Source published: Feb 27, 2026 · Retrieved: May 4, 2026

    Supports 2 claims
    • Executive company: Executive at EXPONENT INC · Claim reviewed: May 4, 2026
    • Executive title: Executive title: Group Vice President · Claim reviewed: May 4, 2026

  8. Henry Schein, Inc. director board source

    sec filing · Source published: Apr 9, 2025 · Retrieved: May 3, 2026

    Supports 2 claims
    • Board independence: Independent director · Claim reviewed: May 3, 2026
    • Board membership: Serves on the board of Henry Schein, Inc. · Claim reviewed: May 3, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Board independence · Source reportedIndependent director1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · Source reportedServes on the board of Henry Schein, Inc.1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at 908 Devices Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Biohaven Ltd.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · Source reportedExecutive at Exelixis Inc1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive company · Source reportedExecutive at EXPONENT INC1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive company · Source reportedExecutive at Intellia Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive company · Source reportedExecutive at Viking Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive company · Source reportedExecutive at Xencor Inc1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: Chief Scientific Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive title · Source reportedExecutive title: Group Vice President1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Executive title · Source reportedExecutive title: Named Executive Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: President and Chief Executive Officer, Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: President, Chief Executive Officer and Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: Senior Vice President and General Counsel1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 4, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources8 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: Executive company · Executive title

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: Executive company · Executive title

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

    Supports: Executive company · Executive title

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: Executive company · Executive title

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Executive company · Executive title

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 4, 2026

    Supports: Executive company · Executive title

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Board independence